SCHEMBL5455129

SCHEMBL5455129

Cc1ccc(N2N=C(C(C)C)CC2=O)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
KDM4E B2RXH2 6/20 0.46
TDP1 Q9NUW8 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
POLB P06746 2/20 0.46
CASP6 P55212 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
MAPT P10636 8/20 0.46
GAA P10253 3/20 0.46
PKM P14618 1/20 0.46
ALDH1A1 P00352 7/20 0.46
MEN1 O00255 4/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 1/20 0.44
APP P05067 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455119 0.89 KDM4E (0.48) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL4350206 0.87 KMT2A (0.42) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5457558 0.85 KMT2A (0.45) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL4343104 0.82 KMT2A (0.67) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5459978 0.79 MAPT (0.45) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5468382 0.77 MAPT (0.51) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5781892 0.76 MAPT (0.43) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL14107040 0.75 KMT2A (0.69) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5976227 0.74 GAA (0.62) KMT2AKDM4ETDP1L3MBTL1POLB
SCHEMBL5464226 0.73 MAPT (0.43) KMT2AKDM4ETDP1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KMT2A 2948/4885KDM4E 3789/4885TDP1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.